妊娠期糖尿病强化血糖控制:随机对照可行性试验
该随机对照可行性试验纳入60例超重或肥胖的妊娠期糖尿病孕妇,比较强化血糖目标(空腹<90 mg/dL、餐后1小时<120 mg/dL)与标准目标(空腹<95 mg/dL、餐后1小时<140 mg/dL)。强化组需要更多药物治疗(83% vs 57%,P=.02),动态血糖监测显示24小时平均血糖和餐后1小时血糖更低,低血糖不常见且组间无差异。结论认为强化目标可行且低血糖风险小,但能否改善母儿结局需进一步研究。
要点
- 超重或肥胖妊娠期糖尿病孕妇采用强化血糖目标是可行的
- 强化组需要更多药物治疗(83% vs 57%,P=.02)
- 强化组动态血糖监测的24小时平均血糖和餐后1小时血糖更低
核心结论
- 超重或肥胖妊娠期糖尿病孕妇可采用强化血糖目标且低血糖风险小,与标准目标相比可改善血糖控制。
- 强化血糖目标能否改善高危妊娠期糖尿病孕妇的母儿结局尚需进一步研究。
研究设计与样本
- 随机对照临床可行性试验,纳入60例超重或肥胖的妊娠期糖尿病孕妇,随机分为强化组(n=30)和标准组(n=30)。
- 妊娠期糖尿病诊断孕周为12至32周,两组基线特征(母亲年龄、体重指数、诊断时孕周)相似。
- 所有孕妇接受标准化饮食咨询,必要时给予药物治疗以达到血糖控制。
- 血糖评估采用盲法动态血糖监测(在12-32周和32-36周两个时间点各佩戴5天)和每日4次自我血糖监测。
主要发现
- 强化组接受药物治疗的比例高于标准组(83% vs 57%,P=.02)。
- 动态血糖监测显示强化组24小时平均血糖更低(差值-8.1 mg/dL,95%CI -12.0至-4.3,P<.0001)。
- 动态血糖监测显示强化组餐后1小时血糖更低(差值-11.8 mg/dL,95%CI -19.7至-3.9,P=.004)。
- 低血糖<60 mg/dL不常见且组间无差异。
关键数值与推荐
- 强化血糖目标:空腹<90 mg/dL,餐后1小时<120 mg/dL。
- 标准血糖目标:空腹<95 mg/dL,餐后1小时<140 mg/dL。
- 低血糖定义为<60 mg/dL,该事件不常见且组间无差异。
临床怎么用
- 对超重或肥胖的妊娠期糖尿病孕妇可考虑采用强化血糖目标(空腹<90 mg/dL、餐后1小时<120 mg/dL)。
- 采用强化目标时需预期更多孕妇需要药物治疗,并监测低血糖。
- 强化血糖目标对母儿结局的影响尚未明确,需进一步研究验证。
局限性
- 本研究为可行性试验,样本量小(60例),主要评估可行性而非临床结局。
- 研究人群限于超重或肥胖的妊娠期糖尿病孕妇,结论外推需谨慎。
- 能否改善母儿结局尚需进一步研究确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Overweight and obese women with gestational diabetes mellitus are at increased risk for adverse perinatal outcomes, and they are also more likely to have suboptimal glycemic control. However, there is a paucity of data evaluating whether lower glycemic targets could improve outcomes. OBJECTIVE: To evaluate the feasibility of intensive glycemic control in overweight and obese women with gestational diabetes mellitus. MATERIALS AND METHODS: We randomized 60 overweight or obese women with gestational diabetes mellitus, diagnosed between 12 and 32 weeks' gestation to either intensive (fasting <90 mg/dL, 1 hour postprandial <120 mg/dL) or standard (fasting <95 mg/dL, 1 ho postprandial <140 mg/dL) glycemic targets. Maternal glucose was assessed in 2 ways: blinded continuous glucose monitors, worn for 5 days at 2 time points (at 12-32 weeks and again at 32-36 weeks), and self-monitored glucose measurement 4 times per day. All women underwent standardized dietary counseling, and medical therapy was prescribed as needed to achieve glycemic control. RESULTS: Between December 2015 and December 2017, we randomized 60 women to either intensive (n = 30) or standard (n = 30) glycemic control. Baseline characteristics including maternal age, body mass index, and gestational age at diagnosis were similar between the intensive and standard groups. Medical therapy was more common in women in the intensive group than those in the standard group (83 vs 57%, P = .02). Women in the intensive glycemic control group had lower glucose values as assessed by continuous glucose monitors at including 24-hour mean (-8.1; 95% confidence interval, -12.0 to -4.3 mg/dL; P < .0001) and 1-h postprandial (-11.8; 95% confidence interval, -19.7 to -3.9 mg/dL, P = .004) values. Hypoglycemia <60 mg/dL was uncommon and did not differ between groups. CONCLUSION: Intensive glycemic targets can be used in overweight and obese women with minimal hypoglycemia, and this approach results in improved glycemic control when compared to standard glycemic targets. Further studies are needed to determine whether intensive glycemic targets can improve maternal and neonatal outcomes in high-risk women with gestational diabetes mellitus. CLINICAL TRIAL IDENTIFIER: NCT02530866; clinicaltrials.gov.
引用
- Scifres CM, Mead-Harvey C, Nadeau H, et al. Intensive glycemic control in gestational diabetes mellitus: a randomized controlled clinical feasibility trial. Am J Obstet Gynecol MFM. 2019. PMID: 33345840. doi:10.1016/j.ajogmf.2019.100050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。